Hyperlipidaemia News

  • 22 September 2020
    Dr Albert Wiegman, Amsterdam University Medical Center, The Netherlands discusses the latest findings that have highlighted familial hypercholesterolaemia in children. For the second time within 12 months, a study about children with familial hypercholesterolaemia (FH, inherited high cholesterol) is published in The New England Journal of...
  • 07 September 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Henry Ginsberg  The post How much do you have to reduce Lp(a) to achieve significant clinical benefit? appeared first on PCSK9 Forum.
  • 02 September 2020
    Almost all high- and very-high risk patients achieved at least 30% reduction in LDL cholesterol levels with inclisiran adjunctive to maximally tolerated statin therapy, according to this latest analysis from the ORION trial programme, reported at ESC Congress 2020. Inclisiran is a novel siRNA therapeutic that inhibits hepatic synthesis of PCSK9....
  • 02 September 2020
    Early treatment with the PCSK9 inhibitor evolocumab, on top of statin, may provide a feasible therapeutic approach for patients with an acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI), according to this Japanese study. Patients are at highest risk of recurrent events in the early phase after an AMI even with...
  • 01 September 2020
    Only one-third of patients in routine practice attain the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guideline-recommended LDL cholesterol goals, based on the results of the DA-VINCI study. These findings show that implementation of guideline-recommended management will require a practice change, especially...
  • 01 September 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Christie Ballantyne  The post Bempedoic acid: The new kid on the block appeared first on PCSK9 Forum.
  • 01 September 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Robert Rosenson  The post Immunotherapies in homozygous FH: Alirocumab and evinacumab appeared first on PCSK9 Forum.
  • 30 August 2020
    The post Professor Santos discusses HAUSER-RCT appeared first on PCSK9 Forum.
  • 30 August 2020
    Results from the HAUSER-RCT trial show that treatment with evolocumab safely reduced LDL cholesterol by almost 40% against a background of statin and diet, in children and adolescents with heterozygous familial hypercholesterolaemia. Heterozygous familial hypercholesterolaemia (FH) is one of the most common metabolic disorders, affecting about one...
  • 30 August 2020
    HAUSER RCT showed that treatment with the PCSK9 monoclonal antibody evolocumab, against a background of usual care (statin, with ezetimibe in 12-15% of patients), was effective and safe in children and adolescents with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) (1). The question is: Does this therapy have a role...
  • 30 August 2020
    PCSK9 Forum Editor Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) comments on the findings of the HASUER-RCT study and potential implications for patient care. HAUSER-RCT is an important study for the care of children and adolescents with familial hypercholesterolaemia (FH). The study evaluated the PCSK9...
  • 29 July 2020
    People living with human immunodeficiency virus (HIV) infection are at increased risk of atherosclerotic cardiovascular disease (ASCVD) compared with those without this infection despite more extensive use of antiretroviral therapy and increased use of statin therapy (1). This increased risk relates to the presence of impaired coronary endothelial...
  • 28 July 2020
    Alirocumab   Trial Study in Participants With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH) ClinicalTrials.gov Identifier: NCT03156621 Aim To assess low-density lipoprotein cholesterol (LDL-C) reduction with alirocumab in adult patients with HoFH. Study design Randomised, double-blind, placebo-controlled, parallel-group,...
  • 27 July 2020
    According to this report, about half of all patients hospitalised for an acute coronary syndrome (ACS) would be eligible for treatment with a PCSK9 inhibitor, based on the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidaemia guidelines. This contrasts with about one in seven based on the 2018 American...
  • 27 July 2020
    A new analysis from the FOURIER study suggests that lowering LDL cholesterol with evolocumab led to benefit across various myocardial infarction (MI) subtypes linked to plaque rupture. The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) study previously demonstrated significant reduction in...
  • 27 July 2020
    Data from an experimental model provide support for clinically relevant effects of PCSK9 inhibitors in reducing postprandial lipaemia, especially in patients with type 2 diabetes mellitus. Elevated postprandial lipaemia is an independent risk factor for atherosclerotic cardiovascular disease (1). In previous studies using a mouse model, PCSK9...
  • 27 July 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Chris Packard  The post Remnant lipoproteins and impact of PCSK9 inhibition appeared first on PCSK9 Forum.
  • 27 July 2020
    Professor Chris Packard (Institute of Cardiovascular and Medical Sciences, Glasgow University, UK) discusses how PCSK9 inhibition might affect remnant particles.  The case for the causality of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is indisputable (1). Consequently, attention has now focused on the role of triglyceride-...
  • 13 July 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Dr Charles Paulding and Amy Damask  The post Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES appeared first on PCSK9 Forum.
  • 13 July 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Anne Tybjaerg-Hansen  The post Genetic risk scores: How much do they add? appeared first on PCSK9 Forum.

Pages